Anest. intenziv. Med. 2009;20(1):37-47

Guidelines for the treatment of invasive candidiasisGuidelines

Haber Jan1,*, Ráčil Zdenek2, Mayer Jiří2, Mallátová Naďa3, Kouba Michal4, Sedláček Petr5, Faber Edgar6, Herold Ivan7, Múdry Peter8, Drgoňa Luboš9, Kocmanová Iva10, Karas Michal11, Buchta Vladimír12, Vydra Jan13, Kolář Michal14, Trupl Jan15, Marešová Vilma16, Rozsypal Hanuš16, Nyč Otakar17, Cwiertka Karel18
1 I. interní klinika - klinika hematologie VFN, Praha
2 Interní hematoonkologická klinika FN Brno
3 Laboratoř lékařské parazitologie a mykologie, Centrální laboratoře, Nemocnice České Budějovice, a. s.
4 Ústav hematologie a krevní transfuze Praha
5 Klinika dětské hematologie a onkologie FN Motol, Praha
6 Hematoonkologická klinika FN Olomouc
7 ARO, Klaudiánova nemocnice Mladá Boleslav
8 Klinika dětské onkologie, FN Brno
9 Národný onkologický ústav, Bratislava, Slovensko
10 Oddělení klinické mikrobiologie FN Brno
11 Hematologicko-onkologické oddělení FN Plzeň
12 Ústav klinické mikrobiologie FN Hradec Králové
13 Oddělení klinické hematologie FNKV, Praha
14 KAR VFN, Praha
15 Klinika laboratorní medicíny SYNLAB, s. r. o., Bratislava, Slovensko
16 Infekční klinika FN Na Bulovce, Praha
17 Ústav lékařské mikrobiologie FN Motol, Praha
18 Onkologická klinika FN Olomouc

A national task force representing clinicians (haematologists, oncologists, microbiologists and intensivists), specialist medical societies and working groups prepared evidence-based guidelines for the treatment of established fungal infections - invasive candidiasis - in adult haematology and ICU patients. These guidelines updated those published in the Czech Republic in 2003/2004. The quality of the clinical trials was assessed using the evidence criteria of the Infectious Diseases Society of America (IDSA) and the updated EORTC/MSG Consensus Group conclusions were used for definitions of invasive fungal disease.

Keywords: invasive candidiasis; candidaemia; treatment guidelines

Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Haber J, Ráčil Z, Mayer J, Mallátová N, Kouba M, Sedláček P, et al.. Guidelines for the treatment of invasive candidiasis. Anest. intenziv. Med. 2009;20(1):37-47.
Download citation

References

  1. Morgan, J., Meltzer, M. I., Plikaytis, B. D. et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control. Hosp. Epidemiol., 2005, 26, p. 540-547. Go to original source... Go to PubMed...
  2. Pfaller, M., Wenzel, R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur. J. Clin. Microbiol. Infect. Dis., 1992, 11, p. 287-291. Go to original source... Go to PubMed...
  3. Beck-Sague, C., Jarvis, W. R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis., 1993, 167, p. 1247-1251. Go to original source... Go to PubMed...
  4. Kao, A. S., Brandt, M. E., Pruitt, W. R. et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis., 1999, 29, p. 1164-1170. Go to original source... Go to PubMed...
  5. Diekema, D. J., Messer, S. A., Brueggemann, A. B. et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol., 2002, 40, p. 1298-1302. Go to original source... Go to PubMed...
  6. Hajjeh, R. A., Sofair, A. N., Harrison, L. H. et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol., 2004, 42, p. 1519-1527. Go to original source... Go to PubMed...
  7. Abi-Said, D., Anaissie, E., Uzun, O. et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis., 1997, 24, p. 1122-1128. Go to original source... Go to PubMed...
  8. Goodman, J. L., Winston, D. J., Greenfield, R. A. et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med., 1992, 326, p. 845-851. Go to original source... Go to PubMed...
  9. Laverdiere, M., Rotstein, C., Bow, E. J. et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J. Antimicrob. Chemother., 2000, 46, p. 1001-1008. Go to original source... Go to PubMed...
  10. Junghanss, C., Marr, K. A. Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr. Opin. Infect. Dis., 2002, 15, p. 347-353. Go to original source... Go to PubMed...
  11. Gudlaugsson, O., Gillespie, S., Lee, K. et al. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis., 2003, 37, p. 1172-1177. Go to original source... Go to PubMed...
  12. Marr, K. A. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr. Opin. Infect. Dis., 2000, 13, p. 615-620. Go to original source... Go to PubMed...
  13. Kami, M., Machida, U., Okuzumi, K. et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br. J. Haematol., 2002, 117, p. 40-46. Go to original source... Go to PubMed...
  14. Sendid, B., Cotteau, A., Francois, N. et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect. Dis., 2006, 6, p. 80. Go to original source... Go to PubMed...
  15. Eggimann, P., Garbino, J., Pittet, D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis., 2003, 3, p. 685-702. Go to original source... Go to PubMed...
  16. Pappas, P. G., Rex, J. H., Lee, J. et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis., 2003, 37, p. 634-643. Go to original source... Go to PubMed...
  17. Ostrosky-Zeichner, L., Pappas, P. G. Invasive candidiasis in the intensive care unit. Crit. Care Med., 2006, 34, p. 857-863. Go to original source... Go to PubMed...
  18. Trick, W. E., Fridkin, S. K., Edwards, J. R. et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis., 2002, 35, p. 627-630. Go to original source... Go to PubMed...
  19. Wisplinghoff, H., Bischoff, T., Tallent, S. M. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis., 2004, 39, p. 309-317. Go to original source... Go to PubMed...
  20. Asmundsdottir, L. R., Erlendsdottir, H., Gottfredsson, M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J. Clin. Microbiol., 2002, 40, p. 3489-3492. Go to original source... Go to PubMed...
  21. Poikonen, E., Lyytikainen, O., Anttila, V. J., Ruutu, P. Candidemia in Finland, 1995-1999. Emerg. Infect. Dis., 2003, 9, p. 985-990. Go to original source... Go to PubMed...
  22. Almirante, B., Rodriguez, D., Park, B. J. et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance. Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol., 2005, 43, p. 1829-1835. Go to original source... Go to PubMed...
  23. Sandven, P., Bevanger, L., Digranes, A. et al. Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group. J. Clin. Microbiol., 1998, 36, p. 3455-3459. Go to PubMed...
  24. Sandven, P., Bevanger, L., Digranes, A. et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol., 2006, 44, p. 1977-1981. Go to original source... Go to PubMed...
  25. Richet, H., Roux, P., Des Champs, C. et al. Candidemia in French hospitals: incidence rates and characteristics. Clin. Microbiol. Infect., 2002, 8, p. 405-412. Go to original source... Go to PubMed...
  26. Rodriguez, D., Almirante, B., Park, B. J. et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr. Infect. Dis. J., 2006, 25, p. 224-229. Go to original source... Go to PubMed...
  27. McNeil, M. M., Nash, S. L, Hajjeh, R. A. et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis., 2001, 33, p. 641-647. Go to original source... Go to PubMed...
  28. Hobson, R. P. The global epidemiology of invasive Candida infections - is the tide turning? J. Hosp. Infect., 2003, 55, p. 159-168; quiz 233. Go to original source... Go to PubMed...
  29. Marr, K. A., Seidel, K., Slavin, M. A. et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood, 2000, 96, p. 2055-2061. Go to original source...
  30. Marr, K. A. Invasive Candida infections: the changing epidemiology. Oncology, (Williston Park) 2004, 18, p. 9-14.
  31. Chamilos, G., Luna, M., Lewis, R. E. et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica, 2006, 91, p. 986-989. Go to PubMed...
  32. Peman, J., Canton, E., Gobernado, M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur. J. Clin. Microbiol. Infect. Dis., 2005, 24, p. 23-30. Go to original source... Go to PubMed...
  33. Pfaller, M. A., Diekema, D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev., 2007, 20, p. 133-163. Go to original source... Go to PubMed...
  34. Nguyen, M. H., Peacock, J. E., Jr., Morris, A. J. et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med., 1996, 100, p. 617-623. Go to original source... Go to PubMed...
  35. Antoniadou, A., Torres, H. A., Lewis, R. E. et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore), 2003, 82, p. 309-321. Go to original source... Go to PubMed...
  36. Marchetti, O., Bille, J., Fluckiger, U. et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis., 2004, 38, p. 311-320. Go to original source... Go to PubMed...
  37. Martin, D., Persat, F., Piens, M. A., Picot, S. Candida species distribution in bloodstream cultures in Lyon, France, 1998-2001. Eur. J. Clin. Microbiol. Infect. Dis., 2005, 24, p. 329-333. Go to original source... Go to PubMed...
  38. Richardson, M. D. Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother., 2005, 56, Suppl 1, i5-i11. Go to original source... Go to PubMed...
  39. Boktour, M. R., Kontoyiannis, D. P., Hanna, H. A. et al. Multiple-species candidemia in patients with cancer. Cancer, 2004, 101, p. 1860-1865. Go to original source... Go to PubMed...
  40. Tortorano, A. M., Caspani, L., Rigoni, A. L. et al. Candidosis in the intensive care unit: a 20-year survey. J. Hosp. Infect., 2004, 57, p. 8-13. Go to original source... Go to PubMed...
  41. Dimopoulos, G., Karabinis, A., Samonis, G., Falagas, M. E. Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. Eur. J. Clin. Microbiol. Infect. Dis., 2007, 26, p. 377-384. Go to original source... Go to PubMed...
  42. Tortorano, A. M., Peman, J., Bernhardt, H. et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis., 2004, 23, p. 317-322. Go to original source... Go to PubMed...
  43. Buchta, V. M. K., Bergerová, T. Výskyt potenciálně patogenních kvasinek v krvi a moči pacientů ve velkých nemocnicích v České republice. Klin. Mikrobiol. Inf. Lék., 1998, 4, p. 10-17.
  44. Hamal, P., Dobiášová, S., Kocmanová, I. Candidemia in large Czech hospitals, 2000-2002: An epidemiological study. In 15th Congress of the International Society for Human and Animal Mycology. San Antonio, 2003; p. 463.
  45. Hamal, P., Kocmanová, I., Jedličková, A. et al. Epidemiological analysis of candidemia in Czech tertiary care hospitals in 2000-2006. J. Chemother., 2007, 19 (suppl. 3), S61-S62.
  46. Krcmery, V., Jr., Kovacicova, G. Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study group. Diagn. Microbiol. Infect. Dis., 2000, 36, p. 7-11. Go to original source... Go to PubMed...
  47. Drgona, L., Trupl, J., Roidova, A. et al. Fungaemia in Slovakia: a prospective, national study.. ECCMID 2008, Barcelona. 2008.
  48. Rex, J. H., Bennett, J. E., Sugar, A. M. et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin. Infect. Dis., 1995, 21, p. 994-996. Go to original source... Go to PubMed...
  49. Rex, J. H., Walsh, T. J., Sobel, J. D. et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis., 2000, 30, p. 662-678. Go to original source... Go to PubMed...
  50. Luzzati, R., Amalfitano, G., Lazzarini, L. et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis., 2000, 19, p. 602-607. Go to original source... Go to PubMed...
  51. Walsh, T. J., Rex, J. H. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin. Infect. Dis., 2002, 34, p. 600-602. Go to original source... Go to PubMed...
  52. Viudes, A., Peman, J., Canton, E. et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis., 2002, 21, p. 767-774. Go to original source... Go to PubMed...
  53. Fatkenheuer, G., Buchheidt, D., Cornely, O. A. et al. Central venous catheter (CVC)-related infections in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol., 2003, 82, Suppl 2, S149-157. Go to original source... Go to PubMed...
  54. Fatkenheuer, G., Cornely, O., Seifert, H. Clinical management of catheter-related infections. Clin. Microbiol. Infect., 2002, 8, p. 545-550. Go to original source... Go to PubMed...
  55. Maki, D. G., Crnich, C. J. Line sepsis in the ICU: prevention, diagnosis, and management. Semin. Respir. Crit. Care Med., 2003, 24, p. 23-36. Go to original source... Go to PubMed...
  56. Pappas, P. G., Rex, J. H., Sobel, J. D. et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis., 2004, 38, p. 161-189. Go to original source... Go to PubMed...
  57. Pasqualotto, A. C., de Moraes, A. B., Zanini, R. R., Severo, L. C. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect. Control. Hosp. Epidemiol., 2007, 28, p. 799-804. Go to original source... Go to PubMed...
  58. Karlowicz, M. G., Hashimoto, L. N., Kelly, R. E., Jr., Buescher, E. S. Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics, 2000, 106, E63. Go to original source... Go to PubMed...
  59. Nucci, M., Anaissie, E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin. Infect. Dis., 2002, 34, p. 591-599. Go to original source... Go to PubMed...
  60. Mermel, L. A., Farr, B. M., Sherertz, R. J. et al. Guidelines for the management of intravascular catheter-related infections. Clin. Infect. Dis., 2001, 32, p. 1249-1272. Go to original source... Go to PubMed...
  61. O'Grady, N. P., Alexander, M., Dellinger, E. P. et al. Guidelines for the prevention of intravascular catheter-related infections. Infect. Control. Hosp. Epidemiol., 2002, 23, p. 759-769. Go to original source... Go to PubMed...
  62. Vescia, S., Baumgartner, A. K., Jacobs, V. R. et al. Management of venous port systems in oncology: a review of current evidence. Ann. Oncol., 2008, 19, p. 9-15. Go to original source... Go to PubMed...
  63. Nguyen, M. H., Peacock, J. E., Jr., Tanner, D. C. et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch. Intern. Med., 1995, 155, p. 2429-2435. Go to original source... Go to PubMed...
  64. Lecciones, J. A., Lee, J. W., Navarro, E. E. et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin. Infect. Dis., 1992, 14, p. 875-883. Go to original source... Go to PubMed...
  65. Nucci, M., Colombo, A. L., Silveira, F. et al. Risk factors for death in patients with candidemia. Infect. Control. Hosp. Epidemiol., 1998, 19, p. 846-850. Go to original source... Go to PubMed...
  66. Kibbler, C. C., Seaton, S., Barnes, R. A. et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect., 2003, 54, p. 18-24. Go to original source... Go to PubMed...
  67. Aliyu, S. H., Enoch, D. A., Abubakar, I. I. et al. Candidaemia in a large teaching hospital: a clinical audit. QJM, 2006, 99, p. 655-663. Go to original source... Go to PubMed...
  68. Nucci, M., Anaissie, E. Revisiting the source of candidemia: skin or gut? Clin. Infect. Dis., 2001, 33, p. 1959-1967. Go to original source... Go to PubMed...
  69. Blot, F., Schmidt, E., Nitenberg, G. et al. Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis. J. Clin. Microbiol., 1998, 36, p. 105-109. Go to original source... Go to PubMed...
  70. Raad, I., Hanna, H., Maki, D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect. Dis., 2007, 7, p. 645-657. Go to original source... Go to PubMed...
  71. Pasqualotto, A. C., Severo, L. C. The importance of central venous catheter removal in patients with candidaemia: time to rethink our practice? Clin. Microbiol. Infect., 2008, 14, p. 2-4. Go to original source... Go to PubMed...
  72. Anaissie, E. J., Rex, J. H., Uzun, O., Vartivarian, S. Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med., 1998, 104, p. 238-245. Go to original source... Go to PubMed...
  73. Pearson, M. L. Guideline for prevention of intravascular device-related infections. Hospital Infection Control Practices Advisory Committee. Infect. Control. Hosp. Epidemiol., 1996, 17, p. 438-473. Go to original source... Go to PubMed...
  74. Seifert, H., Cornely, O., Seggewiss, K. et al. Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis. J. Clin. Microbiol., 2003, 41, p. 118-123. Go to original source... Go to PubMed...
  75. Blot, F., Nitenberg, G., Chachaty, E. et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet, 1999, 354, p. 1071-1077. Go to original source... Go to PubMed...
  76. Kite, P., Dobbins, B. M., Wilcox, M. H., McMahon, M. J. Rapid diagnosis of central-venous-catheter-related bloodstream infection without catheter removal. Lancet, 1999, 354, p. 1504-1507. Go to original source... Go to PubMed...
  77. Bouza, E., Alvarado, N., Alcala, L. et al. A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal. Clin. Infect. Dis., 2007, 44, p. 820-826. Go to original source... Go to PubMed...
  78. Bouza, E., Alvarado, N., Alcala, L. et al. A prospective, randomized, and comparative study of 3 different methods for the diagnosis of intravascular catheter colonization. Clin. Infect. Dis., 2005, 40, p. 1096-1100. Go to original source... Go to PubMed...
  79. Maki, D. G., Weise, C. E., Sarafin, H. W. A semiquantitative culture method for identifying intravenous-catheter-related infection. N. Engl. J. Med., 1977, 296, p. 1305-1309. Go to original source... Go to PubMed...
  80. Sherertz, R. J., Raad, I. I., Belani, A. et al. Three-year experience with sonicated vascular catheter cultures in a clinical microbiology laboratory. J. Clin. Microbiol., 1990, 28, p. 76-82. Go to original source... Go to PubMed...
  81. Morrell, M., Fraser, V. J., Kollef, M. H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother., 2005, 49, p. 3640-3645. Go to original source... Go to PubMed...
  82. Garey, K. W., Rege, M., Pai, M. P. et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis., 2006, 43, p. 25-31. Go to original source... Go to PubMed...
  83. Rex, J. H., Bennett, J. E., Sugar, A. M. et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med., 1994, 331, p. 1325-1330. Go to original source... Go to PubMed...
  84. Herbrecht, R., Flückiger, U., Gachot, B. et al. 2007 update of the ECIL-1 guidelines for Antifungal therapy in leukemia patients. In 2nd European Conference on Infections in Leukemia, Edition Juan-les-Pins-France 2007.
  85. Kish, M. A. Guide to development of practice guidelines. Clin. Infect. Dis., 2001, 32, p. 851-854. Go to original source... Go to PubMed...
  86. Edwards, J. E., Jr., Bodey, G. P., Bowden, R. A. et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin. Infect. Dis., 1997, 25, p. 43-59. Go to original source... Go to PubMed...
  87. Bohme, A., Ruhnke, M., Buchheidt, D. et al. Treatment of fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol., 2003, 82 Suppl 2, S133-140. Go to original source... Go to PubMed...
  88. Slavin, M. A., Szer, J., Grigg, A. P. et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern. Med. J., 2004, 34, p. 192-200. Go to original source... Go to PubMed...
  89. Herbrecht, R., Fluckiger, U., Gachot, B. et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur. J. Cancer Supplements, 2007, 5, p. 49-59. Go to original source...
  90. Horn, D., Neofytos, D., Fishman, J. et al. Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. Eur. J. Clin. Microbiol. Infect. Dis., 2007, 26, p. 907-914. Go to original source... Go to PubMed...
  91. Patel, M., Kunz, D. F., Trivedi, V. M. et al. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn. Microbiol. Infect. Dis., 2005, 52, p. 29-34. Go to original source... Go to PubMed...
  92. Anaissie, E. J., Darouiche, R. O., Abi-Said, D. et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis., 1996, 23, p. 964-972. Go to original source... Go to PubMed...
  93. Phillips, P., Shafran, S., Garber, G. et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur. J. Clin. Microbiol. Infect. Dis., 1997, 16, p. 337-345. Go to original source... Go to PubMed...
  94. Kullberg, B. J., Sobel, J. D., Ruhnke, M. et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet, 2005, 366, p. 1435-1442. Go to original source... Go to PubMed...
  95. Anaissie, E. J., Vartivarian, S. E., Abi-Said, D. et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med., 1996, 101, p. 170-176. Go to original source... Go to PubMed...
  96. Nolla-Salas, J., Sitges-Serra, A., Leon-Gil, C. et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med., 1997, 23, p. 23-30. Go to original source... Go to PubMed...
  97. Mora-Duarte, J., Betts, R., Rotstein, C. et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med., 2002, 347, p. 2020-2029. Go to original source... Go to PubMed...
  98. Kuse, E. R., Chetchotisakd, P., da Cunha, C. A. et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, 2007, 369, p. 1519-1527. Go to original source... Go to PubMed...
  99. Reboli, A. C., Rotstein, C., Pappas, P. G. et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med., 2007, 356, p. 2472-2482. Go to original source... Go to PubMed...
  100. Rex, J. H., Pappas, P. G., Karchmer, A. W. et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis., 2003, 36, p. 1221-1228. Go to original source... Go to PubMed...
  101. Graninger, W., Presteril, E., Schneeweiss, B. et al. Treatment of Candida albicans fungaemia with fluconazole. J. Infect., 1993, 26, p. 133-146. Go to original source... Go to PubMed...
  102. Kontoyiannis, D. P., Bodey, G. P., Mantzoros, C. S. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses, 2001, 44, p. 125-135. Go to original source... Go to PubMed...
  103. Barrett, J. P., Vardulaki, K. A., Conlon, C. et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther., 2003, 25, p. 1295-1320. Go to original source... Go to PubMed...
  104. Kleinberg, M. What is the current and future status of conventional amphotericin B? Int. J. Antimicrob. Agents, 2006, 27, Suppl 1, p. 12-16. Go to original source... Go to PubMed...
  105. Torrado, J. J., Espada, R., Ballesteros, M. P., Torrado-Santiago, S. Amphotericin B formulations and drug targeting. J. Pharm. Sci., 2008, 97, p. 2405-2425. Go to original source... Go to PubMed...
  106. Eriksson, U., Seifert, B., Schaffner, A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ, 2001, 322, p. 579-582. Go to original source... Go to PubMed...
  107. Furrer, K., Schaffner, A., Vavricka, S. R. et al. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med. Wkly., 2002, 132, p. 316-320. Go to original source... Go to PubMed...
  108. Imhof, A., Walter, R. B., Schaffner, A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin. Infect. Dis., 2003, 36, p. 943-951. Go to original source... Go to PubMed...
  109. Peleg, A. Y., Woods, M. L. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J. Antimicrob. Chemother., 2004, 54, p. 803-808. Go to original source... Go to PubMed...
  110. Wingard, J. R., Kubilis, P., Lee, L. et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis., 1999, 29, p. 1402-1407. Go to original source... Go to PubMed...
  111. Bates, D. W., Su, L., Yu, D. T. et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis., 2001, 32, p. 686-693. Go to original source... Go to PubMed...
  112. Bates, D. W., Su, L., Yu, D. T. et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int., 2001, 60, p. 1452-1459. Go to original source... Go to PubMed...
  113. Mayer, J., Doubek, M., Doubek, J. et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J. Infect. Dis., 2002, 186, p. 379-388. Go to original source... Go to PubMed...
  114. Mayer, J., Doubek, M., Vorlicek, J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support. Care Cancer, 1999, 7, p. 51-55. Go to original source... Go to PubMed...
  115. Johnson, J. R. Reduction of nephrotoxicity associated with amphotericin B deoxycholate. Clin. Infect. Dis., 2004, 38, p. 303; author reply p. 306-307. Go to original source... Go to PubMed...
  116. Ito, J. I., Hooshmand-Rad, R. Treatment of Candida infections with amphotericin B lipid complex. Clin. Infect. Dis., 2005, 40, Suppl 6, S384-391. Go to original source... Go to PubMed...
  117. Anaissie, E. J., White, M. H., Uzun, O. et al. Amphotericin B Lipid Complex vs Amphotericin B for Treatment of invasive Candidiasis: A Prospective, Randomized Multicenter Trial. In ICAAC 35th, Interscience Conference on Antimicrobial Agents and Chemotherapy, Edition San Francisco: 1995.
  118. Noskin, G., Pietrelli, L., Gurwith, M., Bowden, R. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant, 1999, 23, p. 697-703. Go to original source... Go to PubMed...
  119. Noskin, G. A., Pietrelli, L., Coffey, G. et al. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin. Infect. Dis., 1998, 26, p. 461-467. Go to original source... Go to PubMed...
  120. Walsh, T. J., Hiemenz, J. W., Seibel, N. L. et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis., 1998, 26, p. 1383-1396. Go to original source... Go to PubMed...
  121. Tuil, O., Cohen, Y. Itraconazole IV solution in the treatment of candidemia in non-neutropenic patients. Critical Care Medicine, 2003, 7, P131-P132. Go to original source...
  122. Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J. et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis., 2005, 24, p. 654-661. Go to original source... Go to PubMed...
  123. Abbas, J., Bodey, G. P., Hanna, H. A. et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch. Intern. Med., 2000, 160, p. 2659-2664. Go to original source... Go to PubMed...
  124. Safdar, A., Chaturvedi, V., Cross, E. W. et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob. Agents. Chemother., 2001, 45, p. 2129-2133. Go to original source... Go to PubMed...
  125. Safdar, A., van Rhee, F., Henslee-Downey, J. P. et al. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant., 2001, 28, p. 873-878. Go to original source... Go to PubMed...
  126. Bodey, G. P., Mardani, M., Hanna, H. A. et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med., 2002, 112, p. 380-385. Go to original source... Go to PubMed...
  127. Safdar, A., Chaturvedi, V., Koll, B. S. et al. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob. Agents Chemother., 2002, 46, p. 3268-3272. Go to original source... Go to PubMed...
  128. Safdar, A., Perlin, D. S., Armstrong, D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn. Microbiol. Infect. Dis., 2002, 44, p. 11-16. Go to original source... Go to PubMed...
  129. Bennett, J. E., Izumikawa, K., Marr, K. A. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother., 2004, 48, p. 1773-1777. Go to original source... Go to PubMed...
  130. Pfaller, M. A., Messer, S. A., Boyken, L. et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J. Clin. Microbiol., 2004, 42, p. 3142-3146. Go to original source... Go to PubMed...
  131. Panackal, A. A., Gribskov, J. L., Staab, J. F. et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol., 2006, 44, p. 1740-1743. Go to original source... Go to PubMed...
  132. Herbrecht, R., Denning, D. W., Patterson, T. F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med., 2002, 347, p. 408-415. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.